according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Mometasone Cream Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS

EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

## **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2 H315: Causes skin irritation.

Eye irritation, Category 2 H319: Causes serious eye irritation.

Long-term (chronic) aquatic hazard, Cat-H411: Toxic to aquatic life with long lasting effects.

egory 2

#### 2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



Signal word : Warning

Hazard statements : H315 Causes skin irritation.

H319 Causes serious eye irritation.

H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P264 Wash skin thoroughly after handling.P273 Avoid release to the environment.

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

P280 Wear protective gloves/ eye protection/ face protection.

Response:

P332 + P313 If skin irritation occurs: Get medical advice/

attention.

P337 + P313 If eye irritation persists: Get medical advice/

attention.

P391 Collect spillage.

#### **Additional Labelling**

EUH212 Warning! Hazardous respirable dust may be formed when used. Do not breathe

dust.

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
2-Methyl-2,4-pentanediol	107-41-5 203-489-0 603-053-00-3	Skin Irrit. 2; H315 Eye Irrit. 2; H319	>= 10 - < 20
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410  M-Factor (Chronic aquatic toxicity): 100	>= 0.1 - < 0.25

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Causes skin irritation.

Causes serious eye irritation.

## 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

#### **SECTION 5: Firefighting measures**

## 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Vapours may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

## 5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

## 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine the control of th

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

## 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

#### **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

according to Regulation (EC) No. 1907/2006

## Public → ORGANON

## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe vapours.

Do not swallow.

Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

## 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage

Advice on common storage

areas and containers

Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Do not store with the following product types:

Strong oxidizing agents

Organic peroxides Explosives

Gases

7.3 Specific end use(s)

Specific use(s) : No data available

#### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
White mineral oil (petroleum)	8042-47-5	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL
	Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used			
2-Methyl-2,4- pentanediol	107-41-5	OELV - 15 min (STEL)	25 ppm 125 mg/m3	IE OEL
Titanium dioxide	13463-67-7	OELV - 8 hrs	4 mg/m3	IE OEL

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

		(TWA) (Respira- ble dust)		
	Further information: Where no specific short-term exposure limit is listed, a			
	figure three times the long-term exposure limit value should be used			
		OELV - 8 hrs	10 mg/m3	IE OEL
		(TWA) (inhalable		
		dust)		
	Further information: Where no specific short-term exposure limit is listed, a			
	figure three times the long-term exposure limit value should be used			
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 μg/100 cm <sup>2</sup>	Internal

These substance(s) are inextricably bound in the product and therefore do not contribute to a dust inhalation hazard.

Titanium dioxide

## Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
2-Methyl-2,4- pentanediol	Workers	Inhalation	Long-term systemic effects	44.4 mg/m3
	Workers	Inhalation	Long-term local ef- fects	49 mg/m3
	Workers	Inhalation	Acute local effects	98 mg/m3
	Workers	Skin contact	Long-term systemic effects	42 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	7.8 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	25 mg/m3
	Consumers	Inhalation	Acute local effects	49 mg/m3
	Consumers	Skin contact	Long-term systemic effects	15 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	1.5 mg/kg bw/day

## Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
2-Methyl-2,4-pentanediol	Fresh water	0.429 mg/l
	Marine water	0.043 mg/l
	Freshwater - intermittent	4.29 mg/l
	Sewage treatment plant	20 mg/l
	Fresh water sediment	1.59 mg/kg dry weight (d.w.)
	Marine sediment	0.159 mg/kg dry weight (d.w.)
	Soil	0.066 mg/kg dry weight (d.w.)

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

#### 8.2 Exposure controls

#### **Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

## **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Physical state : cream

Colour : white to off-white Odour : No data available Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

ange

No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

Lower explosion limit / Lower :

flammability limit

No data available

Flash point : > 93.3 °C

Auto-ignition temperature : No data available

Decomposition temperature

Decomposition tempera-

ture

No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

## **SECTION 10: Stability and reactivity**

## 10.1 Reactivity

Not classified as a reactivity hazard.

## 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Vapours may form explosive mixture with air.

Can react with strong oxidizing agents.

#### 10.4 Conditions to avoid

according to Regulation (EC) No. 1907/2006

# **A**Public → ORGANON

## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

#### **SECTION 11: Toxicological information**

## 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Skin contact exposure Ingestion

Eye contact

**Acute toxicity** 

Not classified based on available information.

#### **Components:**

## 2-Methyl-2,4-pentanediol:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of :

administration)

LD50 (Rat): 300 mg/kg

Application Route: Subcutaneous Symptoms: Breathing difficulties

## Skin corrosion/irritation

Causes skin irritation.

## Components:

## 2-Methyl-2,4-pentanediol:

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

Result : Skin irritation

Remarks : Based on harmonised classification in EU regulation

1272/2008, Annex VI

Mometasone:

Species : Rabbit

Result : No skin irritation

#### Serious eye damage/eye irritation

Causes serious eye irritation.

#### **Components:**

#### 2-Methyl-2,4-pentanediol:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Mometasone:

Species : Rabbit

Result : No eye irritation

## Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

#### 2-Methyl-2,4-pentanediol:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

## Mometasone:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitiser.

## Germ cell mutagenicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

#### **Components:**

## 2-Methyl-2,4-pentanediol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

#### Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral

Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

#### Mometasone:

Species : Rat

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

Application Route : Inhalation Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

## Reproductive toxicity

Not classified based on available information.

#### **Components:**

#### 2-Methyl-2,4-pentanediol:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion
Method: OECD Test Guideline 421

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion
Method: OECD Test Guideline 414

Result: negative

#### Mometasone:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.015 mg/kg body weight

Symptoms: Reduced embryonic survival, Reduced foetal

weiaht

Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-

tal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on

sexual function and fertility, based on animal experiments.

#### STOT - single exposure

Not classified based on available information.

#### **Components:**

#### Mometasone:

Remarks : Based on available data, the classification criteria are not met.

#### STOT - repeated exposure

Not classified based on available information.

## **Components:**

#### Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

#### **Components:**

#### 2-Methyl-2,4-pentanediol:

Species : Rat

NOAEL : >= 450 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Method : OECD Test Guideline 408

#### Mometasone:

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

Species : Rat

NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

NOAEL : 0.00013 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

Species : Dog

NOAEL : 0.0005 mg/l

Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

#### **Aspiration toxicity**

Not classified based on available information.

#### Components:

#### Mometasone:

Not applicable

## 11.2 Information on other hazards

#### **Endocrine disrupting properties**

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **Experience with human exposure**

#### **Components:**

#### 2-Methyl-2,4-pentanediol:

Eye contact : Target Organs: Eyes

Symptoms: Irritation

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

**Further information** 

Components:

Mometasone:

Remarks : Dermal absorption possible

## **SECTION 12: Ecological information**

## 12.1 Toxicity

## **Components:**

2-Methyl-2,4-pentanediol:

Toxicity to fish : LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC10 (Pseudokirchneriella subcapitata (green algae)): > 429

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : NOEC : 200 mg/l

Exposure time: 10 d

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006



## Mometasone Cream Formulation

Revision Date: Date of last issue: 10.10.2020 Version SDS Number: 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.00014 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.34 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility

toxicity)

M-Factor (Chronic aquatic 100

#### 12.2 Persistence and degradability

#### **Components:**

#### 2-Methyl-2,4-pentanediol:

Biodegradability Result: Readily biodegradable.

Biodegradation: 81 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Mometasone:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

according to Regulation (EC) No. 1907/2006



## Mometasone Cream Formulation

Version Date of last issue: 10.10.2020 Revision Date: SDS Number: 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

Stability in water Hydrolysis: 50 %(12 d)

Method: OECD Test Guideline 111

#### 12.3 Bioaccumulative potential

#### **Components:**

#### 2-Methyl-2,4-pentanediol:

Partition coefficient: n-: log Pow: 0

octanol/water Remarks: Calculation

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

> Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 4.68

## 12.4 Mobility in soil

#### **Components:**

## Mometasone:

Distribution among environ- : log Koc: 4.02

mental compartments

## 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

#### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

#### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

#### 14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Mometasone)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Mometasone)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Mometasone)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Mometasone)

IATA : Environmentally hazardous substance, solid, n.o.s.

(Mometasone)

## 14.3 Transport hazard class(es)

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

## 14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

**IMDG** 

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen- : 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

**ADN** 

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

**IMDG** 

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.0 09.04.2021 1699540-00010 Date of first issue: 21.05.2017

Remarks : Not applicable for product as supplied.

#### **SECTION 15: Regulatory information**

## 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de-

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EC) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2

E2 ENVIRONMENTAL 200 t 500 t

**HAZARDS** 

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

: Not applicable

Not applicable

Not applicable

lines.

**Full text of H-Statements** 

H315 : Causes skin irritation.

H319 : Causes serious eye irritation.

H360Df : May damage the unborn child. Suspected of damaging fertili-

tv.

H373 : May cause damage to organs through prolonged or repeated

exposure if inhaled.

H410 : Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

Skin Irrit. : Skin irritation

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Occupational Exposure

Limit Values - Schedule 1

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min : Occupational exposure limit value (15-minute reference period)

(STEL) od)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level: NOELR - No Observable Effect Loading Rate: NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Skin Irrit. 2 H315 Calculation method
Eye Irrit. 2 H319 Calculation method
Aquatic Chronic 2 H411 Calculation method

according to Regulation (EC) No. 1907/2006



## **Mometasone Cream Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.0
 09.04.2021
 1699540-00010
 Date of first issue: 21.05.2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN